Lynx1 Capital Management LP bought $146k of TCRX
owner at TScan Therapeutics, Inc.. 161,801 shares at an average of $0.90, traded Dec 19, 2025, filed Dec 23, 2025.
Score components
- +12Role10% owner
- +11Trade size$146k at market
- 0Relative to holdingsHoldings up 2.1%
- +18Price context0% above the 52-week low; 71% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +29.5%, 3m +13.1%, 6m +1.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-25-005396, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +80,069 | $0.90 | $72k | 7,937,416 | Dec 23, 2025 |
| Dec 22, 2025 | POpen-market purchase Common Stockindirect: See footnote | +75,500 | $0.90 | $68k | 8,012,916 | Dec 23, 2025 |
| Dec 23, 2025 | POpen-market purchase Common Stockindirect: See footnote | +6,232 | $0.90 | $5,602 | 8,019,148 | Dec 23, 2025 |
Related signals
Other insiders at TScan Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $3.1M 2,588,794 shares | +48% | |
| 28Weak | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $386k 131,800 shares | +3% | |
| 2Weak | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $4,114 947 shares | +0% | |
| 36Weak | TCRXbuy TScan Therapeutics, Inc. | Barbara Klencke director | $26k 5,000 shares | +13% | |
| 36Weak | TCRXbuy TScan Therapeutics, Inc. | Barbara Klencke director | $56k 10,000 shares | +33% | |
| 44Moderate | TCRXsell TScan Therapeutics, Inc. | Zoran Zdraveski See Remarks | $952k 164,686 shares | -97% | |
| 52Moderate | TScan Therapeutics, Inc. | Timothy J Barberich director | $142k 29,147 shares | +77% | |
| 38Weak | TScan Therapeutics, Inc. | Barbara Klencke director | $25k 5,000 shares | +20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.